Evidence map›Paper›PMID 38557102›Full record

ArticleMicrobiology spectrum2024

Metagenomic next-generation sequencing of nasopharyngeal microbiota in COVID-19 patients with different disease severities.

Waleed Aljabr, Iman Dandachi, Basma Abbas, Alaa Karkashan, Ahod Al-Amari, Dayel AlShahrani

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Waleed AljabrResearch Center, King Fahad Medical City, Riyadh, Saudi Arabia.ORCID 0000-0002-9385-2776
Iman DandachiResearch Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Basma AbbasDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Alaa KarkashanDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Ahod Al-AmariDepartment of Basic Medical Sciences, College of Medicine, Dar Al-Uloom University, Riyadh, Saudi Arabia.
Dayel AlShahraniPediatric infectious diseases, King Fahad Medical City, Riyadh, Saudi Arabia.
King Fahd Medical City · SAUniversity of Jeddah · SADar Al Uloom University · SAUniversity of Liverpool · GB

Funding

HHS | U.S. Food and Drug Administration (FDA) 75F40120C00085King Fahad Medical City (KFMC) 021-017
6 · The paper itself

Abstract

Throughout the COVID-19 pandemic, extensive research has been conducted on SARS-COV-2 to elucidate its genome, prognosis, and possible treatments. However, few looked at the microbial markers that could be explored in infected patients and that could predict possible disease severity. The aim of this study is to compare the nasopharyngeal microbiota of healthy subjects, moderate, under medication, and recovered SARS-COV-2 patients. In 2020, 38 nasopharyngeal swabs were collected from 6 healthy subjects, 14 moderates, 10 under medication and 8 recovered SARS-COV-2 patients at the Prince Mohammed Bin Abdulaziz Hospital Riyadh. Metatranscriptomic sequencing was performed using Minion Oxford nanopore sequencing. No significant difference in alpha as well as beta diversity was observed among all four categories. Nevertheless, we have found that

Indexed as

COVID-19High-Throughput Nucleotide SequencingMicrobiotaNasopharynxSARS-CoV-2AdultAgedBacteriaFemaleHumansMaleMetagenomeMetagenomicsMiddle AgedSeverity of Illness IndexStreptococcus pneumoniaeCOVID-19disease severitymetatranscriptomicsmicrobiome

Identifiers

PMID38557102
PMCPMC11237758
OpenAlexW4393387316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.